U.S. Markets closed

Streamline Health Solutions, Inc. (STRM)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.0600+0.0500 (+2.49%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close2.0100
Open2.0300
Bid2.0300 x 1000
Ask2.0900 x 1100
Day's Range2.0101 - 2.0799
52 Week Range0.7200 - 3.8600
Volume52,227
Avg. Volume1,900,368
Market Cap87.174M
Beta (5Y Monthly)0.85
PE Ratio (TTM)343.33
EPS (TTM)0.0060
Earnings DateApr 22, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Streamline Health® Reports Fourth Quarter and Fiscal Year 2020 Financial Results
    GlobeNewswire

    Streamline Health® Reports Fourth Quarter and Fiscal Year 2020 Financial Results

    Fiscal 2020 Revenues of $11.3 million; $0.3 million Net Income; Adjusted EBITDA ($1.9 million) Atlanta, GA, April 21, 2021 (GLOBE NEWSWIRE) -- Streamline Health Solutions, Inc. (NASDAQ: STRM), provider of the eValuator™ Revenue Integrity Program to help healthcare providers proactively address revenue leakage and compliance exposure, today announced financial results for the fourth quarter and fiscal year 2020, which ended January 31, 2021. Total revenues for the fourth quarter of fiscal 2020 were $3.0 million, compared to $2.7 million in the prior year period. SaaS revenue was up $349,000, approximately 50%, compared to the same quarter a year ago. The revenue growth during the quarter was driven by higher revenue from SaaS, system sales and professional services offset by lower revenue form audit services and maintenance and support. Recurring revenue comprised 75% of fourth quarter fiscal 2020 revenue compared to 80% of fourth quarter fiscal 2019 revenue. Fiscal year 2020 revenue was $11.3 million, compared to $11.9 million during fiscal 2019. SaaS revenue in fiscal 2020 grew 46% to $3.7 million compared to $2.5 million during fiscal 2019. Recurring revenue comprised 74% of revenue during fiscal 2020 compared to 68% during the prior year. Net loss for the fourth quarter of fiscal 2020 was ($1.2 million) as compared to a net loss of ($2.4 million) during the fourth quarter of fiscal 2019. Fourth quarter fiscal 2020 net loss included $400,000 income from gain from sale, and discontinued operations of the Company’s legacy ECM business which closed February 24, 2020, compared to $18,000 income from discontinued operations during the fourth quarter of fiscal 2019. Income from discontinued operations was offset by a loss from continuing operations for the three months ended January 31, 2021 and 2020 of ($1.6 million) and ($2.4 million), respectively. The company recorded $0.3 million of net income for the fiscal year 2020, compared to a net loss of ($2.9 million) during fiscal 2019. Fiscal year 2020 net income included $5.1 million income from discontinued operations in connection with the sale of the Company’s legacy ECM business which closed February 24, 2020, compared to $3.3 million income from discontinued operations during fiscal 2019. The income from discontinued operations was offset by a loss from continuing operations during fiscal 2020 of ($4.8 million) as compared to a loss of ($6.2 million) during fiscal 2019. Adjusted EBITDA for the fourth quarter of fiscal 2020 was a loss of ($0.1 million), compared to an adjusted EBITDA loss of ($0.6 million) in the fourth quarter of fiscal 2019. Fiscal year 2020 adjusted EBITDA was a loss of ($1.9 million) compared to a loss of ($2.3 million) during fiscal 2019. The profitability improvements have come from cost containment activities in all areas of our business. “Last year was a very difficult and challenging one, especially for COVID patients and healthcare providers throughout the country. Today, with more Americans receiving vaccinations, we believe a ‘return to normalcy’ during the second half of this year is a real possibility. And that should free up departmental decision making, helping us generate more eValuator contracts from our pipeline which grew throughout 2020”, stated Tee Green, President and Chief Executive Officer, Streamline Health. “As the pandemic slowed contract closings, we asked our employees to focus on improving operations and preparing for growth. This internal focus enabled us to develop a top-level product management team to continually expand and improve our eValuator technology and build a superior customer success team to ensure customer satisfaction. I believe all of this will serve us well going forward.” Highlights from the fourth quarter ended January 31, 2021 included: Revenue for the fourth quarter of fiscal 2020 was $3.0 million; SaaS revenue grew 50% compared to the fourth quarter of fiscal 2019;Loss from continuing operations for the fourth quarter of fiscal 2020 was ($1.6 million);Adjusted EBITDA for the fourth quarter of fiscal 2020 was ($0.1 million);Total bookings (total contract value) for the fourth quarter of fiscal 2020 were $1.8 million. Conference Call The Company will conduct a conference call to review the results on Thursday, April 22, 2021 at 9:00 AM ET. Interested parties can access the call by joining the live webcast: click here to register. You can also join by phone by dialing 877-269-7756. A replay of the conference call will be available from Thursday, April 22, 2021 at 12:00 PM ET to Thursday, April 29, 2021 at 12:00 PM ET by dialing 877-660-6853 or 201-612-7415 with conference ID 13716445. An online replay of the presentation will also be available for six months following the presentation in the Investor Relations section of the Streamline Health website, www.streamlinehealth.net. Non-GAAP Financial Measures Streamline Health reports its financial results in accordance with U.S. generally accepted accounting principles ("GAAP"). Streamline Health's management also evaluates and makes operating decisions using various other measures. One such measure is adjusted EBITDA, which is a non-GAAP financial measure. Streamline Health's management believes that this measure provides useful supplemental information regarding the performance of Streamline Health's business operations. Streamline Health defines "adjusted EBITDA" as net earnings (loss) plus interest expense, tax expense, depreciation and amortization expense of tangible and intangible assets, stock-based compensation expense, significant non-recurring operating expenses, and transactional related expenses including: gains and losses on debt and equity conversions, associate severances and related restructuring expenses, associate inducements, and professional and advisory fees. A table illustrating this measure is included in this press release. About Streamline Health Streamline Health Solutions, Inc. (NASDAQ: STRM) is a leader in pre-bill revenue integrity solutions for healthcare providers. Our eValuator™ Revenue Integrity Program includes integrated solutions, technology-enabled services and analytics that drive compliant revenue and improved financial performance across the enterprise. We share a common calling and commitment to advance the quality of life and the quality of healthcare - for society, our clients, the communities they serve, and the individual patient. For more information, please visit our website at www.streamlinehealth.net. Safe Harbor statement under the Private Securities Litigation Reform Act of 1995 Statements made by Streamline Health Solutions, Inc. that are not historical facts are forward-looking statements that are subject to certain risks, uncertainties and important factors that could cause actual results to differ materially from those reflected in the forward-looking statements included herein. Forward-looking statements contained in this press release include, without limitation, statements regarding the Company's growth prospects, estimates of backlog, industry trends and market growth, results of investments in sales and marketing, adjusted EBITDA, success of future products and related expectations and assumptions. These risks and uncertainties include, but are not limited to, the timing of contract negotiations and execution of contracts and the related timing of the revenue recognition related thereto, the potential cancellation of existing contracts or clients not completing projects included in the backlog, the impact of competitive solutions and pricing, solution demand and market acceptance, new solution development and enhancement of current solutions, key strategic alliances with vendors and channel partners that resell the Company's solutions, the ability of the Company to control costs, the effects of cost-containment measures implemented by the Company, availability of solutions from third party vendors, the healthcare regulatory environment, potential changes in legislation, regulation and government funding affecting the healthcare industry, healthcare information systems budgets, availability of healthcare information systems trained personnel for implementation of new systems, as well as maintenance of legacy systems, fluctuations in operating results, effects of critical accounting policies and judgments, changes in accounting policies or procedures as may be required by the Financial Accounting Standards Board or other similar entities, changes in economic, business and market conditions impacting the healthcare industry generally and the markets in which the Company operates and nationally, and the Company's ability to maintain compliance with the terms of its credit facilities, and other risks detailed from time to time in the Streamline Health Solutions, Inc. filings with the U. S. Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect management's analysis only as of the date hereof. The Company undertakes no obligation to publicly release the results of any revision to these forward-looking statements, which may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law. ContactRandy SalisburySVP, Chief Sales & Marketing Officer(404) 229-4242Randy.salisbury@streamlinehealth.net STREAMLINE HEALTH SOLUTIONS, INC.CONSOLIDATED AND CONDENSED STATEMENTS OF OPERATIONS(Unaudited) Three Months Ended Twelve Months Ended January 31 January 31 2021 2020 2021 2020 Revenues: Systems sales$356,000 $153,000 $590,000 $1,121,000 Professional services 145,000 78,000 618,000 1,163,000 Audit Services 393,000 446,000 1,891,000 1,712,000 Maintenance and support 1,030,000 1,303,000 4,586,000 5,356,000 Software as a service 1,050,000 701,000 3,661,000 2,501,000 Total revenues 2,974,000 2,681,000 11,346,000 11,853,000 Operating expenses: Cost of systems sales 116,000 457,000 501,000 1,004,000 Cost of professional services 264,000 330,000 1,040,000 1,592,000 Cost of audit services 400,000 306,000 1,558,000 1,255,000 Cost of maintenance and support 156,000 172,000 684,000 676,000 Cost of software as a service 653,000 352,000 1,906,000 824,000 Selling, general and administrative 1,706,000 2,021,000 8,565,000 9,606,000 Research and development 987,000 940,000 2,933,000 2,690,000 Executive Transition Costs - 168,000 - 789,000 Rationalization Charges - 388,000 - 388,000 Transaction Costs - 230,000 - 230,000 Loss on exit of membership agreement - - 105,000 - Total operating expenses 4,282,000 5,364,000 17,292,000 19,054,000 Operating loss (1,308,000) (2,683,000) (5,946,000) (7,201,000)Other expense: Interest expense (12,000) (70,000) (51,000) (309,000)Miscellaneous expense 6,000 (167,000) (62,000) (366,000)Loss before income taxes (1,314,000) (2,920,000) (6,059,000) (7,876,000)Income tax benefit (276,000) 498,000 1,260,000 1,632,000 Loss from continuing operations$(1,590,000) $(2,422,000) $(4,799,000) $(6,244,000)Add: Redemption of Series A Preferred Stock - - - 4,894,000 Net (loss) income from continuing operations (1,590,000) (2,422,000) (4,799,000) (1,350,000)Income from discontinued operations: Gain on sale of discontinued operations - - 6,013,000 - Income from discontinued operations 51,000 522,000 356,000 5,035,000 Income tax benefit (expense) 352,000 (504,000) (1,274,000) (1,654,000)Income from discontinued operations 403,000 18,000 5,095,000 3,381,000 Net (loss) income$(1,187,000) $(2,404,000) $296,000 $2,031,000 Basic Earnings per Share: Continuing operations$(0.05) $(0.08) $(0.16) $(0.06)Discontinued operations 0.01 - 0.17 0.14 Net (loss) income$(0.04) $(0.08) $0.01 $0.08 Weighted average number of common shares - basic 30,528,863 29,653,550 30,152,383 22,739,679 Diluted Earnings per Share: Continuing operations$(0.05) $(0.08) $(0.16) $(0.27)Discontinued operations 0.01 - 0.17 0.13 Net (loss) income$(0.04) $(0.08) $0.01 $(0.14) Weighted average number of common shares – diluted 31,211,252 30,096,177 30,640,742 25,083,061 STREAMLINE HEALTH SOLUTIONS, INC.CONSOLIDATED AND CONDENSED BALANCE SHEETS(Unaudited) Assets January 31, January 31, 2021 2020Current assets: Cash and cash equivalents$2,409,000 $1,649,000Accounts receivable, net 2,929,000 2,016,000Contract receivables 174,000 803,000Prepaid hardware and other current assets1,216,000 501,000Current Assets from discontinued operations 587,000 1,585,000Total current assets 7,315,000 6,554,000 Non-current assets: Property and equipment, net 104,000 98,000Right of use asset on operating lease 391,000 -Capitalized software development costs, net5,945,000 5,782,000Intangible assets, net 624,000 1,115,000Goodwill 10,712,000 10,712,000Other non-current assets 873,000 611,000Long-term assets from discontinued operations13,000 6,826,000Total non-current assets 18,662,000 25,144,000 $25,977,000 $31,698,000 Liabilities and Stockholders' EquityCurrent liabilities: Accounts payable$272,000 $756,000Accrued expenses 908,000 1,395,000Current portion of term loan 1,534,000 3,872,000Deferred revenues 3,862,000 3,593,000Royalty liability - 969,000Current portion of operating lease obligation198,000 -Current liabilities from discontinued operations595,000 5,053,000Total current liabilities 7,369,000 15,638,000 Non-current liabilities: Term loan, net of current portion 767,000 -Deferred revenues, less current portion 130,000 55,000Operating Lease obligations, less current portion222,000 -Total non-current liabilities 1,119,000 55,000Total liabilities 8,488,000 15,693,000 Stockholders' equity 17,489,000 16,005,000 $25,977,000 $31,698,000 STREAMLINE HEALTH SOLUTIONS, INC.CONSOLIDATED AND CONDENSED STATEMENT OF CASH FLOWS(Unaudited) Fiscal Year Ended January 31, 2021 2020 Cash flows from continuing operating activities: Loss from continuing operations$(4,799,000) $(6,244,000)Depreciation 64,000 43,000 Amortization of capitalized software development costs1,662,000 1,494,000 Amortization of intangible assets 491,000 554,000 Amortization of other deferred costs 359,000 480,000 Valuation adjustments 31,000 64,000 Loss on exit of membership agreement 105,000 - Loss on early extinguishment of debt - 150,000 Share-based compensation expense 1,403,000 934,000 Benefit for accounts receivable allowance (31,000) (201,000)Benefit for income taxes (1,274,000) (1,654,000)Changes in assets and liabilities (1,504,000) (1,329,000)Net cash used in operating activities (3,493,000) (5,709,000)Net cash from operating activities - discontinued operations(2,264,000) 5,701,000 Cash flows used in investing activities: Purchases of property and equipment (44,000) (52,000)Capitalization of software development costs (1,784,000) (2,800,000)Proceeds from sale of ECM assets 11,288,000 - Net cash provided by (used in) investing activities 9,460,000 (2,852,000)Net cash used in investing activities - discontinued operations- (558,000) Cash flows from financing activities: Proceeds from issuance of common stock - 9,663,000 Payments for costs directly attributable to the issuance of common stock- (711,000)Proceeds from term loan 2,301,000 4,000,000 Principal payments on term loan (4,000,000) (4,030,000)Redemption of Series A Convertible Preferred Stock (5,791,000)Other (1,244,000) (440,000)Net cash used in financing activities (2,943,000) 2,691,000 Net decrease in cash and cash equivalents 760,000 (727,000)Cash and cash equivalents at beginning of year 1,649,000 2,376,000 Cash and cash equivalents at end of year 2,409,000 $1,649,000 STREAMLINE HEALTH SOLUTIONS, INC.New Bookings(Unaudited) January 31, 2021 Three Months Ended Twelve Months EndedSystems Sales$203,000 $560,000Professional Services 175,000 808,000Audit Services 37,000 114,000Maintenance and Support 203,000 583,000Software as a Service 1,200,000 5,327,000Q4 2020 Bookings$1,818,000 $7,392,000Q4 2019 Bookings (1)$763,000 $7,892,000 (1) January 31, 2020 excludes bookings from the ECM business of approximately $242,000 for the three months ended January 31, 2020 and $731,000 for the twelve months ended January 31, 2020. STREAMLINE HEALTH SOLUTIONS, INC.Reconciliation of loss from continuing operations to non-GAAP Adjusted EBITDA (in thousands)(Unaudited) Three Months Ended January 31, Twelve Months Ended January 31, 2021 2020 2021 2020 Loss from continuing operations$(1,590) $(2,422) $(4,799) $(6,244) Interest expense 12 70 51 309 Income tax (benefit) expense 276 (498) (1,260) (1,632) Depreciation 17 11 64 43 Amortization of capitalized software development costs534 661 1,662 1,494 Amortization of intangible assets 121 130 491 554 Amortization of other costs 117 272 359 480 EBITDA (513) (1,776) (3,432) (4,996) Share-based compensation expense 400 214 1,403 934 Impairment of long-lived assets - - - - Loss on disposal of fixed assets - - - - Non-cash valuation adjustments (9) 17 31 64 Loss on exit of operating lease - - 105 - Other non-recurring operating expenses - 786 - 1,342 Other non-recurring expenses - 150 - 308 Adjusted EBITDA$(122) $(609) $(1,893) $(2,348) Adjusted EBITDA per diluted share: Net loss per common share – diluted$(0.05) $(0.08) $(0.16) $(0.27) Adjusted EBITDA per adjusted diluted share (1)$- $(0.02) $(0.06) $(0.10) Diluted weighted average shares (2) 30,528,863 29,653,550 30,152,383 22,739,679 Includable incremental shares — Adjusted EBITDA (3) 682,389 442,627 488,359 2,343,382 Adjusted diluted shares 31,211,252 30,096,177 30,640,742 25,083,061 (1) Adjusted EBITDA per adjusted diluted share for our common stock is computed using the more dilutive of the two-class method or the if-converted method.(2) Diluted EPS for our common stock was computed using the if-converted method, which yields the same result as the two-class method.(3) The number of incremental shares that would be dilutive under an assumption that the Company is profitable during the reported period, which is only applicable for a period in which the Company reports a GAAP net loss. If a GAAP profit is earned in the reported periods, no additional incremental shares are assumed.

  • Streamline Health® To Report Fourth Quarter and Fiscal Year 2020 Financial Performance on April 21, 2021
    GlobeNewswire

    Streamline Health® To Report Fourth Quarter and Fiscal Year 2020 Financial Performance on April 21, 2021

    ATLANTA, GA, April 15, 2021 (GLOBE NEWSWIRE) -- Streamline Health Solutions, Inc. (NASDAQ: STRM), provider of the eValuator™ Revenue Integrity Program to help healthcare providers proactively address revenue leakage and compliance exposure, today announced that it will release its financial results for the three and twelve month periods ended January 31, 2021 on Wednesday, April 21, 2021 after the close of the financial markets. The Company will conduct a conference call to review the results on Thursday, April 22, 2021 at 9:00 AM ET. Interested parties can access the call by joining the live webcast: click here to register. You can also join by phone by dialing 877-269-7756. A replay of the conference call will be available from Thursday, April 21, 2021 at 12:00 PM ET to Thursday, April 28, 2021 at 12:00 PM ET by dialing 877-660-6853 or 201-612-7415 with conference ID 13716445. An online replay of the presentation will also be available for six months following the presentation in the Investor Relations section of the Streamline Health website, www.streamlinehealth.net. About Streamline Health Streamline Health Solutions, Inc. (NASDAQ: STRM) is a leader in pre-bill revenue integrity solutions for healthcare providers. Our eValuator™ Revenue Integrity Program includes integrated solutions, technology-enabled services and analytics that drive compliant revenue and improved financial performance across the enterprise. We share a common calling and commitment to advance the quality of life and the quality of healthcare - for society, our clients, the communities they serve, and the individual patient. For more information, please visit our website at www.streamlinehealth.net. Company Contact Randy Salisbury Senior Vice President, Sales & Marketing Streamline Health 404.229.4242 randy.salisbury@streamlinehealth.net

  • Midwestern Medical Center Signs New Contract for Streamline Health® eValuator™
    GlobeNewswire

    Midwestern Medical Center Signs New Contract for Streamline Health® eValuator™

    Automated Coding Analysis for Inpatient and Outpatient Care ATLANTA, April 07, 2021 (GLOBE NEWSWIRE) -- Streamline Health Solutions, Inc. (NASDAQ: STRM), provider of the eValuator™ Revenue Integrity Program to help healthcare providers proactively address revenue leakage and compliance exposure, today announced it has signed a contract with a 287-bed, Meditech EMR-based health system in Northern Ohio. As an opportunity created by Streamline’s network of channel partners, this regional provider will use eValuator’s cloud-based automated pre- and post-bill coding analysis technology to help improve revenue integrity for their inpatient and outpatient services. Streamline Health is leading an industry movement to enable every hospital in the country to use pre-bill technology to improve financial performance. With eValuator, providers are identifying and addressing coding issues before they contribute to revenue leakage, denied claims and non-compliance exposure. The company combines this new technology with expert auditing services to deliver a complete Revenue Integrity Program to its clients. The eValuator program helps users optimize coding and documentation accuracy for every patient encounter prior to billing, substantially improving current financial performance while also assisting in the transition to new payment models. “It’s very encouraging to partner with yet another Midwestern organization and to add to our roster of Meditech-based customers,” stated Tee Green, President and Chief Executive Officer, Streamline Health. “Providers of all sizes are equally committed to ensuring revenue integrity and improving their financial performance, and we’re honored to help them achieve both goals.” About Streamline Health Streamline Health Solutions, Inc. (NASDAQ: STRM) is a leader in pre-bill revenue integrity solutions for healthcare providers. Our eValuator™ Revenue Integrity Program includes integrated solutions, technology-enabled services and analytics that drive compliant revenue and improved financial performance across the enterprise. We share a common calling and commitment to advance the quality of life and the quality of healthcare - for society, our clients, the communities they serve, and the individual patient. For more information, please visit our website at www.streamlinehealth.net. To Learn MoreRandy SalisburySenior Vice President, Sales & MarketingStreamline Health404.229.4242 randy.salisbury@streamlinehealth.net